Paclitaxel
Introduction
Paclitaxel (PTX) is a natural hydrophobic diterpenoid extraction from the bark of the Pacific yew. As mitotic inhibitor, paclitaxel can stabilize and protect microtubules from disassembly, and then interfere with the normal breakdown of microtubules during cell proliferation. As an effective cancer chemotherapy agent, it has been widely used for the treatment of various tumors, including ovarian, breast, non-small cell lung, and prostate tumors [1e3] . Therefore, its commercial formulation (Taxol Ò , Bristol-Myers Squibb, New York, NY) has been comprehensively used in clinic treatment [4e6] . For example, it has been used for the first-line and second-line treatment of ovarian cancer and nonsmall cell lung cancer which is unsuitable for curative treatment. To achieve better chemotherapy efficacy, it is necessary to timely monitor the pharmaceutical pharmacokinetic parameters after intravenous administration.
Analytical methods for determination of paclitaxel in plasma have already been reported. Earlier methods concentrated on the high performance liquid chromatography (HPLC) with UV detector [7e9] . However, its application has been severely limited due to its weakness of sensitivity and long run time. Later, with the development of MS detector, liquid chromatography-mass spectrometry (LC-MS) method [10, 11] and liquid chromatography-tandem mass spectrometry (LC-MS/MS) are widely used for determination of paclitaxel in biological samples. Vainchtein LD et al. [12] used an LC-MS/MS method to determine plasma concentration of paclitaxel with an LLOQ of 0.25 ng/ml, but the chromatographic separation time was longer than 6 min and the plasma spiked volume was 200 ml. With the introduction of ultra-performance liquid chromatography (UPLC), the analysis efficiency has been apparently improved. Zhang SQ et al. [13] reported by using UPLC-MS/MS method, the chromatographic separation time was achieved within 2 min with an LLOQ of 5 ng/ml, but this method was only used for the determination of paclitaxel in human plasma.
The aim of this research was to establish and validate a rapid and sensitive method for quantitatively determination the rat plasma concentration of paclitaxel using UPLC-MS/MS technique. The validation results showed this method was accurate, sensitive, high-throughout and suitable for application in pharmacokinetic studies.
2.
Materials and methods
Materials
Paclitaxel (PTX, 99.9% purity) and docetaxel (DTX, internal standard, I.S., 99.9% purity) were obtained from Xi'an Helin Biological Engineering Co. Ltd. (Xi'an, China). Commercial Taxol solution was obtained from Shanghai Quanyu Pharm. Co. (Shanhai, China). Acetonitrile and methanol of HPLCgrade were purchased from Fisher Scientific (Pittsburgh, PA, USA). Ultrapure water (>18 MU) was prepared by Easypure II RF/UV system (Boston, MA, USA). Formic acid of HPLC-grade was purchased from Dikma (Richmond Hill, NY, USA). Diethyl ether of analytical grade was purchased from Concord Tech. Co. (Tianjin, China) and high-purity nitrogen (99.999%) was used. The plasma sample was collected at designated time from the ocular region of the rats after centrifugation for 10 min. All the other reagents were of analytical grade.
UPLC-MS/MS conditions
Analyses were carried on an ACQUITY TQD system (Waters Corp., Milford, MA, USA) equipped with cooling autosampler, column oven and an ACQUITY triple-quadrupole tandem mass spectrometric detection with an electrospray ionization (ESI) interface (Waters Corp., Milford, MA, USA). An ACQUITY UPLCTM BEH C18 column (50 mm Â 2.1 mm, 1.7 mm; Waters Corp, Milford, MA, USA) was used. A gradient elution was used to achieve chromatographic separation with a mobile phase composed of mobile phase A (acetonitrile) and mobile phase B (water, containing 0.1% formic acid). The mobile phase in the gradient elution progress was: 0 min 50% B, 1.6 min 35% B, 2.5 min 50% B and 3 min 50% B. The flow rate was set at 0.2 ml/ min and the column temperature was maintained at 40 C.
The auto-sample temperature was set at 4 C and the injection volume was 10 ml using the partial loop mode for sample injection. The analytical run time for each sample was 3.0 min. From 1.0 to 2.5 min, the elution was injected into the detector, and the remainder was diverted to waste. The separated compounds were detected by a Water Tan 
Preparation of standards and quality control samples
Stock solutions of paclitaxel and I.S. were prepared in acetonitrile at a concentration of 100 mg/ml, respectively. To prepare the working standard PTX solutions of desired concentrations, the PTX stock solution was serially diluted with mobile phase composed of solvent A (acetonitrile, 50%) and solvent B (water, containing 0.1% formic acid, 50%). The 
I.S. working solution was diluted with the mobile phase to a final concentration of 1 mg/ml. Calibration standards were prepared by spiking 50 ml drugfree rat plasma with 50 ml of appropriate PTX standard solutions. The effective concentrations in plasma samples were 5, 10, 50, 100, 200, 500, 1000, 2000 and 5000 ng/ml. The quality control samples were prepared in a similar way to the calibration standards at concentrations of 10, 200 and 4000 ng/ml.
Sample preparation
To a 50 ml of rat plasma, 50 ml of mobile phase and 50 ml of I.S. solution (DTX, 1 mg/ml in the mobile phase) were added. Then the sample mixture was vortexed for 1 min. To extract the sample, 3 ml diethyl ether was added and then vortexed for 3 min, followed by centrifuged at 3500 rpm for 10 min. Then the upper organic layer was taken out and evaporated to dryness under a gentle nitrogen stream at 37 C. The residue was reconstituted by 100 ml of mobile phase. After centrifuged at 13,000Â g for 10 min, a 10 ml aliquot of the supernatant was then injected into the UPLC-MS/MS system for assay.
Method validation
The analytical method for quantitative determination of PTX in rat sample was validated for selectivity, carryover, lower limit of quantification (LLOQ), linearity, accuracy, precision, matrix effect, extraction recovery, and stability. The different validation parameters and the values for accepting the range of validation parameters were in accordance with international guidelines [14] and Food and Drug Administration guidelines (www.fda.gov/cvm). Selectivity was investigated by comparing chromatograms of six different batches of blank plasma obtained from six rats with those of corresponding standard blood samples spiked with PTX and I.S. and a plasma sample obtained after intravenous administration.
Carryover was estimated by six continual injections of an extracted blank sample after the injection of an extracted upper limit of quantitation sample.
Quantitative determination of the plasma samples was based on the ratio of the detector response of paclitaxel to IS. The standard curves in the form of y ¼ A þ BX were calculated by plotting the peak area ratio (Y ) against paclitaxel concentration (X ) using weighted (1/x 2 ) least squares linear regression. During routine analysis, each analytical run was consisted of a set of calibration standards, a set of QC blood samples in duplicate at intervals per batch and the blood samples to be analyzed.
Nine standard plasma samples ranging from 5 to 5000 ng/ ml were used to prepare the calibration standards. LLOQ was defined as the lowest concentration of paclitaxel on the calibration curve. The precision and accuracy were assessed by analyzing six samples which were prepared in six replicates, and the result should be less than 20%. Meanwhile, the signal/ noise ratio should be over 10.
The accuracy, intra-and inter-day precision were assessed using QC samples at three concentration levels (10, 200 and 4000 ng/ml) on three separate days. The accuracy was defined as the relative error (R.E.) and the precision was determined as the relative standard deviation (RSD).
To investigate the matrix effect (ME), six different lots of blank plasma were extracted and the spiked with the analyte at different paclitaxel concentrations (10, 200 and 4000 ng/ml). The corresponding peak areas (A) were then compared with those of the paclitaxel standard solutions in mobile phase (B). There was a matrix effect when the ratio (A/B Â 100) % was <85% or >115%. The matrix effect of I.S. was evaluated in the same procedure.
Extraction recovery of paclitaxel was defined as the ratio between the mean peak area of the regularly extracted samples (10, 200 and 4000 ng/ml) and the mean peak area of spikeafter-extraction plasma samples. The extraction recovery of IS was evaluated in the same way using the medium level of QC as a reference.
The stability of this method including sample posttreatment (in the reconstituted extract at room temperature for 4 h), sample storage (at room temperature for 24 h) and freeze-thaw stability (three cycles) was investigated by analyzing replicates (n ¼ 3) of QC samples (10, 200 and 4000 ng/ ml). The results were compared with those freshly prepared QC samples and the percentage of concentration deviation was calculated.
Pharmacokinetic study
The developed method was used to determine the plasma concentration of paclitaxel in Taxol injection after intravenous administration in six healthy adult female SD rats weighing 220 AE 20 g (Laboratory Animal Center of Shenyang Pharmaceutical University, Shenyang, Liaoning, China). The rats were deprived of food overnight but with free access to water before experiments. All animals investigated in this research were executed according to the Guidelines for the Care and Use of Laboratory Animals approved by the Ethics Committee of Animal Experimentation of Shenyang Pharmaceutical University. The Taxol solution was diluted with 0.9% NaCl to produce a solution with PTX concentration of 1.5 mg/ml. The rats were treated with diluted Taxol solution at dose of 8 mg/kg by intravenous administration. Blood samples were collected into heparinized tubes at 0.0833, 0.167, 0.25, 0.5, 1, 2, 4, 6, 8 and 10 h and centrifuged immediately at 13,000 g for 10 min. Then the plasma was frozen at À80 C for analysis.
Results and discussions

Method development
Paclitaxel has a higher sensitivity achieved by ESI source rather than APCI and a stronger response in the positive-ion 
mode compared with the negative-ion mode. So ESI þ mode was used for the detection of paclitaxel and IS. Through positive ion full-scan spectra, the predominant protonated molecular ion [M þ H] þ for the analytes were 854 and 808.48, respectively. In order to capture the strongest ion intensity, parameters such as ESI source temperature, capillary and cone voltage were optimized. Then in the collision induced dissociation condition, the abundant product irons were obtained at m/z of 286 and 527.3 for paclitaxel and IS, respectively. The product-ion spectra of these compounds are shown in Fig. 1 . In the chromatographic optimizing process, Acetonitrile was used in the mobile phase instead of methanol because of its lower background noise. Adding formic acid could obviously improve detection sensitivity presumably induced by facilitative ionization of the analytes. Therefore, the mobile phase was consisted of water (0.1% formic acid)-acetonitrile. As described in Section 2.2, a gradient elution progress was used to completely separate paclitaxel and IS. The total run time for both the analytes was 3.0 min. From 1.0 to 2.5 min, the elution was injected into the detector, and the remainder was diverted to waste for avoidance the contamination of ion source by impurities.
Protein precipitation and liquideliquid extraction methods were compared during the sample preparation. The former method was discarded because of high noise and the poor LLOQ of only 25 ng/ml. In the liquideliquid extraction method, diethyl ether was used as the extraction solvent, the higher extraction and lower background noise were also obtained. Nevertheless, the extraction recovery was only about 70% when the samples were extracted by 2 ml diethyl ether, so we added 3 ml diethyl ether to improve the extraction recovery. The following steps were conducted as Section 2.4.
3.2.
Method validation
Selectivity
As shown in Fig. 2 , it was obviously that there was no interference from endogenous substances in blood at the retention time of the analytes.
Carryover
Carryover study indicated that the carryover from residues in sampling/switching valves and late-eluting residues in the column was both negligible.
Linearity and LLOQ
The linear regression was obtained between the peak area ratios and the paclitaxel concentration ranging from 5 to 5000 ng/ml in rat plasma. A typical calibration curve equation was:y ¼ 2:18903 Ã x þ 15:2838ðr ¼ 0:9960Þ, where y is the peak area ratio of PTX to IS, and x is the concentration of PTX. This concentration range showed a good linearity (r > 0.99) in all analytical runs. The calibration curve for each run was exhibited in Table 4 . LLOQ was established by this method at concentration of 5 ng/ml for paclitaxel, which was suitable for quantitative determine the plasma concentration of Taxol injection after intravenous administration. The accuracy and precision values of LLOQ were exhibited in Table 1 . Table 2 summarized the accuracy and precision for paclitaxel from QC samples. The data was listed for each day individually. The results showed a good precision that all the values were below 9.64%. The accuracy ranged from À12.33% to 5.98%, which was also acceptable. The results above illustrated that this UPLC-MS/MS method was precise and accurate.
Precision and accuracy
Matrix effect
All the matrix effect ratios (A/B Â 100) % for PTX and I.S. were between 91.73% and 103.39%, which were within the acceptable limits (90.0%e110.0%). This result means that there was no ion suppression and enhancement phenomenon from plasma matrix. The relative errors of all the QC samples in the stability experiment were below 5.5%, which could be seen in Table 3 , indicating that there was no significant degradation of PTX under the condition described previously.
Application
This developed method was successfully used to determine the plasma concentration of paclitaxel after intravenous administration of Taxol injection (8 mg/kg). At designated times, blood sample were collected up to 10 h after intravenous administration. Our preliminary work indicated that the high PTX blood concentrations of the first 30 min samples were out of the calibration range, so these samples were detected after 10 fold dilution. The feasibility of this method was also validated in our previous work (Data not shown).
The mean plasma concentrationetime curve of paclitaxel is shown in Fig. 3 . The results showed that after single dose of 8 mg/kg Taxol solution, the mean half-life (T 1/2 ) and the mean residence time (MRT) were calculated to be 5.85 AE 3.42 h and 2.91 AE 1.07, respectively. The mean area under the plasma concentration versus time curve (AUC 0-N ) was 15.05 AE 3.12 mg h/ml.
Regarding the relatively easy sample preparation method (liquideliquid extraction) and short chromatographic run time (within 3 min), about 200 samples could be analyzed routinely per day. This convenient and rapid method is able to meet the requirements of pharmacokinetic study for paclitaxel.
Conclusion
We have developed and validated a rapid and sensitive UPLC-MS/MS method for quantitatively high-throughput determination of paclitaxel. Through a rapid liquideliquid extraction process, this method was suitable for application in pharmacokinetic studies of paclitaxel in rats after intravenous administration. Concentration (ng/ml) Fig. 3 e Mean plasma concentrationetime curve of paclitaxel after a single intravenous dose of 8 mg/kg to six rats (mean ± SD).
